Abstract: A method for suppressing the expression of a selected gene in a cell, the method comprising introducing into the cell a molecule comprising (1) a nucleic acid binding portion which binds to a site or associated with the selected gene which site is present in a genome and (2) an expression repressor portion, wherein the nucleic acid binding portion comprises an oligonucleotide or oligonucleotide mimic or analogue, and wherein the repressor portion comprises a polypeptide or peptidomimetic. Molecules for use in the methods of the invention are provided. The repressor may be a portion of a histone deacetylase or DNA methylase or polypeptide capable of recruiting a histone deacetylase or DNA methylase.

Abstract: The invention provides novel GLP-1 analogues and compositions comprising such analogues. The compounds of the invention are useful in treating diabetes mellitus and related disorders.

Abstract: A method for suppressing the expression of a selected gene in a cell the method comprising introducing into the cell a molecule comprising (1) a nucleic acid binding portion which binds to a site or associated with the selected gene which site is present in a genome and (2) an expression repressor portion, wherein the nucleic acid binding portion comprises an oligonucleotide or oligonucleotide mimic or analogue, and wherein the repressor portion comprises a polypeptide or peptidomimetic. Molecules for use in the methods of the invention are provided. The repressor may be a portion of a histone deacetylase or DNA methylase or polypeptide capable of recruiting a histone deacetylase or DNA methylase.

Abstract: A method for suppressing the expression of a selected apoptosis-related gene in a cell the method comprising introducing into the cell a molecule comprising (1) a nucleic acid binding portion which binds to a site at or associated with the selected gene which site is present in a genome and (2) a modifying portion, wherein the nucleic acid binding portion comprises an oligonucleotide or oligonucleotide mimic or analogue, and wherein the repressor portion comprises a polypeptide or peptidomimetic. Molecules for use in the methods of the invention are provided. The repressor or modifying portion may be a portion of a histone deacetylase or DNA methylase or polypeptide capable of recruiting a histone deacetylase or DNA methylase. The nucleic acid binding portion may be a triplex forming oligonucleotide (TFO). The apoptosis-related gene may be Bcl-2.

Abstract: A method for suppressing the expression of a selected gene in a cell the method comprising introducing into the cell a molecule comprising (1) a nucleic acid binding portion which binds to a site or associated with the selected gene which site is present in a genome and (2) an expression repressor portion, wherein the nucleic acid binding portion comprises an oligonucleotide or oligonucleotide mimic or analogue, and wherein the repressor portion comprises a polypeptide or peptidomimetic. Molecules for use in the methods of the invention are provided. The repressor may be a portion of a histone deacetylase or DNA methylase or polypeptide capable of recruiting a histone deacetylase or DNA methylase.

Abstract: A polypeptide and analogues thereof inhibit cholesteryl ester transfer protein (CETP). An anti-atherosclerosis composition comprises an anti-atherosclerosis effective amount of the polypeptide and a pharmaceutically-acceptable carrier. An anti-atherosclerosis kit comprises in separate sterile containers at least one unit of the composition containing the polypeptide, one syringe and one needle. An antibody has specificity for the polypeptide of the invention, the baboon CETP 4 kD polypeptide inhibitor, the 1-36 amino acid N-terminal fragment of apo C-I, modified apo A-I (MW: 31 kD) or modified apo E (MW: 41 kD). A method of preventing atherosclerosis in a mammal being predisposed to that condition comprises administering to the mammal a prophylactically effective amount of the polypeptide of the invention, and a method of treating a mammal afflicted with atherosclerosis comprises the administration of a therapeutically effective amount of the polypeptide disclosed herein.

Abstract: A large pore polyamide resin is useful for large peptide and protein (protide) synthesis. A method of preparing the same comprises mixing a dimethylacrylamide monomer with an unsaturated or alkenoyl amine monomer, a cross-linker and water, homogeneously emulsifying the aqueous mixture with an organic solvent in the presence of an emulsifier, adjusting the pH of the aqueous mixture during polymerization to 6-8.5 to produce large pore resin beads, and isolating the beads. The beads may be used as a solid phase substrate for the synthesis of a polyamide/protide conjugate. The polyamide resin/protide conjugate may be used, without separation of the protide from the resin or subsequent purification, for immunizing mammals, including humans, against the protide, for affinity purifying immunological molecules binding to the protide, and for immunoassays.

Abstract: A polypeptide and analogues thereof inhibit cholesteryl ester transfer protein (CETP). An anti-atherosclerosis composition comprises an anti-atherosclerosis effective amount of the polypeptide and a pharmaceutically-acceptable carrier. An anti-atherosclerosis kit comprises in separate sterile containers at least one unit of the composition containing the polypeptide, one syringe and one needle. An antibody has specificity for the polypeptide of the invention, the baboon CETP 4kD polypeptide inhibitor, the 1-36 amino acid N-terminal fragment of apo C-I, modified apo A-I (MW:31kD) or modified apo E (MW:41kD). A method of preventing atherosclerosis in a mammal being predisposed to that condition comprises administering to the mammal a prophylactically effective amount of the polypeptide of the invention, and a method of treating a mammal afflicted with atherosclerosis comprises the administration of a therapeutically affective amount of the polypeptide disclosed herein.

Abstract: A large pore polyamide resin is useful for large peptide and protein (protide) synthesis. A method of preparing the same comprises mixing a dimethylacrylamide monomer with an unsaturated or alkenoyl amine monomer, a cross-linker and water, homogeneously emulsifying the aqueous mixture with an organic solvent in the presence of an emulsifier, adjusting the pH of the aqueous mixture during polymerization to 6-8.5 to produce large pore resin beads, and isolating the beads. The beads may be used as a solid phase substrate for the synthesis of a polyamide/protide conjugate. The polyamide resin/protide conjugate may be used, without separation of the protide from the resin or subsequent purification, for immunizing mammals, including humans, against the protide, for affinity purifying immunological molecules binding to the protide, and for immunoassays.

Abstract: A polyamide resin for use in peptide and protein synthesis, and a method of preparing and using same. The polyamide resin is prepared by mixing a dimethylacrylamide monomer with an N-acrylyl-diaminoalkane functional monomer in an aqueous solution together with a cross-linker and emulsifying the aqueous solution in an organic solvent. An initiator and a promoter are added to polymerize the N-acrylyl-diaminoalkane functional monomer, dimethylacrylamide monomer, and cross-linker in the form of beads. The pH of the mixture is controlled during the polymerization. The beads are used as a solid phase for peptide and protein synthesis according to methods known in the art. The conjugate of the polyamide resin and the synthesized peptide or protein is used directly for immunoassays or immunization without the need for separation of the peptide or protein from the resin and subsequent purification.

Abstract: A polyamide resin for use in peptide and protein synthesis, and a method of preparing and using same. The polyamide resin is prepared by cross-linking a dimethylacrylamide monomer by co-polymerization with a functional monomer in an aqueous solution, emulsifying the aqueous solution in an organic solvent and isolating the polyamide resin beads formed by adding an initiator and a promoter. The beads are used as a solid phase for peptide and protein synthesis according to methods known in the art. The conjugate of the polyamide resin and the synthesized peptide or protein is used directly for immunoassays or immunization without the need for separation of the peptide or protein from the resin and subsequent purification.

Abstract: A polyamide resin for use in peptide and protein synthesis, and a method of preparing and using same. The polyamide resin is prepared by mixing a dimethylacrylamide monomer with an N-acrylyl-diaminoalkane functional monomer in an aqueous solution together with a cross-linker and emulsifying the aqueous solution in an organic solvent. An initiator and a promoter are added to polymerize the N-acrylyl-diaminoalkane functional monomer, dimethylacrylamide monomer, and cross-linker in the form of beads. The pH of the mixture is controlled during the polymeriztion. The beads are used as a solid phase for peptide and protein synthesis according to methods known in the art. The conjugate of the polyamide resin and the synthesized peptide or protein is used directly for immunoassays or immuniaztion without the need for separation of the peptide or protein from the resin and subsequent purification.